Co-administration of paroxetine increased the systemic exposure of pravastatin in diabetic rats due to the decrease in liver distribution

References

• Borders-Hemphill V. (2009). Concurrent use of statins and amiodarone. Consult Pharm 24:372–9
   PubMedGoogle Scholar
• Bottorff MB. (2006). Statin safety and drug interactions: clinical implications. Am J Cardiol 97:27C–31C
   PubMed Web of Science ®Google Scholar
• Chen GM, Hu N, Liu L, et al. (2011). Pharmacokinetics of verapamil in diabetic rats induced by combination of high-fat diet and streptozotocin injection. Xenobiotica 41:494–500
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. (2004). Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–96
   PubMed Web of Science ®Google Scholar
• Ellis LC, Hawksworth GM, Weaver RJ. (2013). ATP-dependent transport of statins by human and rat MRP2/Mrp2. Toxicol Appl Pharmacol 269:187–94
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Kishimoto S, Shibatani N, et al. (2010). The disposition of pravastatin in a rat model of streptozotocin-induced diabetes and organic anion transporting polypeptide 2 and multidrug resistance-associated protein 2 expression in the liver. Biol Pharm Bull 33:153–6
   PubMed Web of Science ®Google Scholar
• Ishigami M, Tokui T, Komai T, et al. (1995). Evaluation of the uptake of pravastatin by perfused rat liver and primary cultured rat hepatocytes. Pharm Res 12:1741–5
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Niemi M. (2009). Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693–705
   PubMed Web of Science ®Google Scholar
• Kobayashi D, Nozawa T, Imai K, et al. (2003). Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 306:703–8
   PubMed Web of Science ®Google Scholar
• Komai T, Kawai K, Tokui T, et al. (1992a). Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys. Eur J Drug Metab Pharmacokinet 17:103–13
   PubMed Web of Science ®Google Scholar
• Komai T, Shigehara E, Tokui T, et al. (1992b). Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem Pharmacol 43:667–70
   PubMed Web of Science ®Google Scholar
• Li F, Zhang M, Xu D, et al. (2014). Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure. Acta Pharmacol Sin 35:792–805
   PubMed Web of Science ®Google Scholar
• Liu C, Zhang M, Hu MY, et al. (2013). Increased glucagon-like peptide-1 secretion may be involved in antidiabetic effects of ginsenosides. J Endocrinol 217:185–96
   PubMed Web of Science ®Google Scholar
• Liu H, Liu L, Li J, et al. (2012). Combined contributions of impaired hepatic CYP2C11 and intestinal breast cancer resistance protein activities and expression to increased oral glibenclamide exposure in rats with streptozotocin-induced diabetes mellitus. Drug Metab Dispos 40:1104–12
   PubMed Web of Science ®Google Scholar
• MacLean C, Moenning U, Reichel A, Fricker G. (2010). Regional absorption of fexofenadine in rat intestine. Eur J Pharm Sci 41:670–4
   PubMed Web of Science ®Google Scholar
• Mei D, Li J, Liu H, et al. (2012). Induction of multidrug resistance-associated protein 2 in liver, intestine and kidney of streptozotocin-induced diabetic rats. Xenobiotica 42:709–18
   PubMed Web of Science ®Google Scholar
• Moreno G, Mangione CM. (2013). Management of cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: 2002–2012 literature review. J Am Geriatr Soc 61:2027–37
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Kajosaari LI, et al. (2005). Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 77:468–78
   PubMed Web of Science ®Google Scholar
• Ogura J, Koizumi T, Segawa M, et al. (2014). Quercetin-3-rhamnoglucoside (rutin) stimulates transport of organic anion compounds mediated by organic anion transporting polypeptide 2B1. Biopharm Drug Dispos 35:173–82
   PubMed Web of Science ®Google Scholar
• Roten L, Schoenenberger RA, Krahenbuhl S, Schlienger RG. (2004). Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 38:978–81
   PubMed Web of Science ®Google Scholar
• Schachter M. (2005). Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19:117–25
   PubMed Web of Science ®Google Scholar
• Tamai I, Takanaga H, Maeda H, et al. (1995). Proton-cotransport of pravastatin across intestinal brush-border membrane. Pharm Res 12:1727–32
   PubMed Web of Science ®Google Scholar
• Tokui T, Nakai D, Nakagomi R, et al. (1999). Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharm Res 16:904–8
   PubMed Web of Science ®Google Scholar
• Varma MV, Lin J, Bi YA, et al. (2013). Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin. Drug Metab Dispos 41:966–74
   PubMed Web of Science ®Google Scholar
• Varma MV, Rotter CJ, Chupka J, et al. (2011). pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm 8:1303–13
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Maeda K, et al. (2009). Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652–62
   PubMed Web of Science ®Google Scholar